Immunogenicity and safety of a primary series of a new fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine (Hexaxim™) co-administered with Prevenar™ and Rotarix™ in healthy children in Latin America

López, Pío; Mohs, Adriano Arguedas; Miranda, Mariano; Zambrano, Betzana; Lima, Elaine S.

doi:10.1016/j.ijid.2012.05.1012

Cited by 4 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For these antigens, GMTs of antibodies were generally higher than those following primary immunization. Similar results were obtained for D and T, whereas seroconversion rates for PT and FHA were ≥92% and ≥87%, respectively . However, while GMTs for D and T after the booster were generally higher than after the primary series, those for PT and FHA were similar or only slightly higher than those obtained after the priming series .…”

Section: Hexyonsupporting

confidence: 79%

“…Similar data were collected in the second study, albeit with a significantly lower number of infants . In two other studies the two hexavalent vaccines were compared in children who received it alongside PCV7 or PCV7 and rotavirus vaccine and who had received a hepatitis B vaccine at birth . In the study by Kosalaraksa et al .…”

Section: Hexyonmentioning

confidence: 69%

“…Moreover, seroprotective levels against P1, P2, P3 and Hib were reached in ≥98%, ≥95%, ≥97 and ≥91% of cases, respectively . Although there is a limit to the absence of PRN, seroconversion rates for acellular pertussis antigens were ≥90% for PT and ≥82% for FHA . After the booster dose, seroprotection rates with Hexyon were consistently 100% for P1, P2, P3 and Hib .…”

Section: Hexyonmentioning

confidence: 93%

“…Similar results were obtained by Lopez et al . who found that infants given Hexyon were seroprotected after primary series in 99.7% of the cases in comparison to 100% of those who received Infanrix hexa, with no observed interference of co‐administration of PCV7 and rotavirus vaccine. Similar antibody GMTs (3013 mIU/mL for the investigational vaccine and 2766 for Infanrix hexa) were detected.…”

Section: Hexyonmentioning

confidence: 98%

“…Immune response was systematically similar to that obtained with comparators. Among the children who had received Hexyon as a primary immunization, the vaccine evoked seroprotective levels of antibody against D and T in ≥95% and 100% of the cases, respectively [64][65][66][67][68][69][70]. Moreover, seroprotective levels against P1, P2, P3 and Hib were reached in ≥98%, ≥95%, ≥97 and ≥91% of cases, respectively [64][65][66][67][68][69][70].…”

Section: Hexyonmentioning

confidence: 99%

See 4 more Smart Citations

Hexavalent vaccines for immunization in paediatric age

Esposito

Tagliabue

Bosis

et al. 2014

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Despite the potential for protection against a broad spectrum of pathogens, the availability of an increased number of effective vaccines could lead to a significant reduction in vaccination coverage as the result of issues with implementation of new vaccines within existing protocols. To overcome these problems, the development of combined vaccines has been promoted. The use of combined vaccines offers a number of potential benefits, including a reduction in the number of patient visits, reduced complications associated with multiple intramuscular injections, decreased costs of stocking and administering separate vaccines, and a lowering of the risk of delayed or missed vaccinations. The hexavalent vaccine includes antigens against diphtheria, tetanus, acellular pertussis (DTaP), hepatitis B (HBsAg), poliomyelitis (P1, P2, P3) and Haemophilus influenzae type B (Hib) infections. The primary goal of this review is to discuss the immunogenicity, efficacy, safety and tolerability of several hexavalent preparations that are either commercially available or still under development.

show abstract

Section: Hexyonsupporting

confidence: 79%

Section: Hexyonmentioning

confidence: 69%

Section: Hexyonmentioning

confidence: 93%

Section: Hexyonmentioning

confidence: 98%

Section: Hexyonmentioning

confidence: 99%

See 3 more Smart Citations

Hexavalent vaccines for immunization in paediatric age

Esposito

Tagliabue

Bosis

et al. 2014

Clinical Microbiology and Infection

View full text Add to dashboard Cite

show abstract

DTaP-IPV-Hep B-Hib vaccine (Hexyon®/Hexacima®): a guide to its use in the primary and booster vaccination of infants and toddlers in Europe

Lyseng‐Williamson¹,

McCormack²

2013

Drugs Ther Perspect

View full text Add to dashboard Cite

DTaP-IPV-Hep B-Hib Vaccine (Hexaxim®)

McCormack¹

2013

Pediatr Drugs

View full text Add to dashboard Cite

Hexaxim(®) (DTaP-IPV-Hep B-Hib) is a new, thiomersal-free, fully liquid, hexavalent combination pediatric vaccine containing diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, recombinant hepatitis B virus surface antigen produced in the yeast Hansenula polymorpha, and Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus toxoid. It is currently registered in markets outside of the EU for primary vaccination of infants from 6 weeks of age and for booster vaccination up to 24 months of age. In randomized controlled trials, primary vaccination of infants with Hexaxim(®) using various immunization schedules was highly immunogenic for all vaccine component antigens regardless of the administration schedule, producing high levels of seroprotection or seroconversion for each antigen. Hexaxim(®) was as immunogenic as the comparator DTwP- or DTaP-based vaccines in these studies. The serological responses were generally sustained at high levels over a follow-up of ≈1 year, and booster vaccination at 15-18 months further enhanced the immune response. Hexaxim(®) was less reactogenic than a DTwP-based combination vaccine, and displayed a tolerability profile similar to those of the comparator DTaP-based combination vaccines. Thus, Hexaxim(®) provides effective seroprotection or seroconversion against six major childhood diseases simultaneously, both as primary and booster vaccination, and offers the benefits and convenience of a fully liquid, ready-to-use vaccine.

show abstract

Immunogenicity and safety of a primary series of a new fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine (Hexaxim™) co-administered with Prevenar™ and Rotarix™ in healthy children in Latin America

Abstract: Conclusion:It can be concluded that the adjuvant property of propolis ethanol extract may be useful for the stimulation of humoral immune responses in vaccine design for infectious disease.

Cited by 4 publications

References 0 publications

Hexavalent vaccines for immunization in paediatric age

Hexavalent vaccines for immunization in paediatric age

DTaP-IPV-Hep B-Hib vaccine (Hexyon®/Hexacima®): a guide to its use in the primary and booster vaccination of infants and toddlers in Europe

DTaP-IPV-Hep B-Hib Vaccine (Hexaxim®)

Contact Info

Product

Resources

About